Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 44, 39, 42, 84, 86.
All papers from the last 12 months
491 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumorsMAbs2026 Dec 31PMID 42271190
- Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeuticsOncoimmunology2026 Dec 31PMID 41700001Review
- NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cellsOncoimmunology2026 Dec 31PMID 41548123
- A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in in vivo and ex vivo modelsOncoimmunology2026 Dec 31PMID 41459935
- Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1MAbs2026 DecPMID 42731893
- Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigensMAbs2026 DecPMID 42680712
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature reviewHum Vaccin Immunother2026 DecPMID 42012232Review
- Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinomaMAbs2026 DecPMID 41804857
- Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLCLung Cancer2026 NovPMID 42804884
- Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challengesCancer Treat Rev2026 NovPMID 42710271Review
More oncology trends
All specialties →Circulating tumour DNA
Liquid biopsy with ctDNA for detection, monitoring and treatment decisions.
Key point: ctDNA testing may be used when tissue testing is challenging, infeasible, risky, delayed, or required by drug indication; negative/inconclusive results should prompt tissue confirmation.
Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point: Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
bispecific*[tiab] AND (tarlatamab[tiab] OR amivantamab[tiab] OR ivonescimab[tiab] OR "solid tumor*"[tiab] OR "lung cancer"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.